Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

JP, thanks for the heads up and link about ototoxi

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30067
Posted On: 06/24/2014 9:48:48 AM
Posted By: Hoosier
Re: jpetroinc #1242
JP, thanks for the heads up and link about ototoxicity.

Here are a few thoughts about it.

Paraphrasing from the article:
"Ototoxicity is a condition which affects the ear causing hearing loss and tinnitus. It is caused by the toxic side affects of over 100 classes of drugs and other pharmacological agents. Management emphasis is on prevention, and substitute medication should be used when appropriate as the damage done is irreversible. Scientists and Clinicians are constantly seeking new methods to reduce the affects of ototoxicity".

I'll repost a portion of Gerald's last blog. Under MANF starting with the fourth paragraph:
Quote:
The Company is also continuing to move forward with other initiatives on the MANF front with Dr. Larry Schwartz at the University of Massachusetts, including the further evaluation of MANF as a treatment for the orphan indication antibiotic-induced ototoxicity, as well as other undisclosed possibilities. - See more at: http://www.thechairmansblog.com/amarantus-bio...q8HoO.dpuf



This is one of the things our Dr. Schwartz has been working on. If MANF can be used to prevent ototoxicity, there are over 100 classes of medications which may become viable for use and commercialization without being "substituted". And in Gerald's blog it specifically states they are seeking "antibiotic-induced ototoxicity"-we all know of the growing demand for new types of antibiotics. They are also seeking a orphan indication. This small aspect of AMBS's initiatives could become a massive division within AMBS itself!

AMBS looks better and better every day!

GLTA,
GO AMBS

Here is a link to the article if you would like to read more about it.

http://emedicine.medscape.com/article/857679-overview


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us